Investee Company – Inpharmatica Ltd (UK)
Investee Company Business Type – Informatics driven drug discovery company
Type of Financing – Expansion
Equity Providers – Dresdner Kleinwort Capital, Abingworth Management, Advent Venture Partners, Gilde Investment, Vertex Management, Genentech Inc, 3i Group plc, Unibio Ltd, GIMV
Equity Leader (Individual) – Daniel Green, Dresdner Kleinwort Capital
Debt Providers – N/A
Debt Type – N/A
Debt Leader (Individual) – N/A
Equity Amount – £31.25 million
Total Deal Value – £31.25 million
Other Advisors – N/A
Comments – Inpharmatica has announced the completion of their second round of financing raising a total of £31.25 million. The placement, on which CSFB advised, was oversubscribed and includes some leading VC’s currently investing in global life science.
Inpharmatica is based in central London and was founded in 1998. It is a structural bioformatics company that focuses on the growing market for bioinformatics tools and databases and the drug discovery market. The financing will be used for establish in-house experimental drug discovery capabilities and further develop excisiting technology.
Patrick Banks, finance director at Inpharmatica said: “Inpharmatica is now well placed to take further advantage of the genomic and proteomic data currently being generated. The money raised will fund our transistion from being a pure information provider into a drug discovery company in our own right.”
The consortium of investors was led by Dresdner Kleinwort Capital and included Abingworth Management, Advent Venture Partners, Gilde Investment and Vertex Management. They were joined by first round investors 3i Group plc, GIMV and seed investor Unibio Ltd.